Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 312-318 , June 2005

Central nervous system metastases in breast cancer patients administered trastuzumab

References 

  1. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12 – 21.32. Genomics. 1989;4:362–366
  2. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes on epidermal growth factor receptor-related protein. Nature. 1986;319:226–230
  3. Van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinase and their signal transduction pathways. Annu Rev Cell Biol. 1994;10:251–337
  4. Hynes NE, Stern DF. The biology of erbB-2/neu/HER 2 and its role in cancer. Biochim Biophys Acta. 1994;1198:165–184
  5. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791–808
  6. Barnes DM, Bartkova J, Camplejohn RS, et al. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?. Eur J Cancer. 1992;28:644–648
  7. Hoque A, Sneige N, Sahin AA, et al. HER 2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002;11:587–590
  8. Pegram MD, Baly D, Wirth C, et al. Antibody dependent cell-mediated cytotoxity in breast cancer patients in phase III clinical trials of a humanized anti-HER 2 antibody [abstract]. Proc Am Assoc Cancer Res. 1997;38:602
  9. Hotaling TE, Reitz B, Wolfgang-Kimball D, Bauer K, et al. The humanized anti-HER 2 antibody rhuMAb HER2/NEU mediates antibody dependent cell-mediated cytotoxity via FcyR III [abstract]. Proc Am Assoc Cancer Res. 1996;37:471
  10. Slamon DJ, Clark GH, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/NEU/neu oncogene. Science. 1987;235:177–182
  11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus monoclonal antibody against HER 2 for metastatic breast cancer that overexpress HER2/NEU. N Engl J Med. 2001;344:783–792
  12. Extra J-M, Cognetti F, Chan S, et al. Randomised phase II (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as a first-line therapy in patients with HER2/NEU positive metastatic breast cancer [abstract]. Eur J Cancer Suppl. 2003;1:S202
  13. Pestalozzi BC. In replay: Baculi RH, Suki S, Nisbett J, et al. Meningeal carcinomatosis from breast carcinoma responive to trastuzumab. J Clin Oncol 2001;19:3298.
  14. Flowers A, Levin VA. Managment of brain metastases from breast carcinoma. Oncology. 1993;7:21–26
  15. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52:2349–2354
  16. Amer M. Chemotherapy and pattern of metastases in breast cancer patients. J Surg Oncol. 1982;19:101–105
  17. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on survival. Ann Oncol. 2003;14:1072–1077
  18. Freilich RJ, Seidman AD, DeAngelis LM, et al. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer. 1995;76:232–236
  19. Crivellari D, Pagani O, Veronesi A, et al. High incidence of central nervous system involment in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol. 2001;12:353–356
  20. Rice A, Michaelis MI, Georg G, et al. Overcoming the blood–brain barrier to taxane delivery from neurodegeneration disease and brain tumors. J Mol Neurosci. 2003;20:339–344
  21. Stewart JF, King RJ, Sexton SA, et al. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer. 1981;17:449–453
  22. Sparrow GE, Rubens RD. Brain metastases from breast cancer: clinical course, prognosis and influence of treatment. Clin Oncol. 1981;7:291–301
  23. Carraway KL, Rossi EA, Komatsu M, et al. An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem. 1999;274:5263–5266
  24. Richt PA, Carroll SL, Sontheimer H. Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. J Biol Chem. 2003;278:20971–20978
  25. DiStefano A, Yong Yap Y, Hortobagyi GN, et al. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44:1913–1918
  26. Schiff D, Batchelor T, Wen PY. Neurologic emergencies in cancer patients. Neurol Clin. 1998;16:449–454
  27. Delattre JY, Krol G, Thaler HT, et al. Distribution of brain metastases. Arch Neurol. 1988;45:741–744
  28. Sondak V, Deckers PJ, Feller JH, et al. Leptomenigeal spread of breast cancer: report of case and review of the literature. Cancer. 1981;48:395–399
  29. Sze G, Milano E, Johnson C, et al. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol. 1999;11:785–791
  30. Wen PY, Black PM, Loeffler JS. Metastatic brain cancer. In:  De Vita VT,  Hellman S,  Rosenberg SA, et al. editor. Cancer: principles and practices of oncology. Philadelphia: Lippincott-Raven; 2001;p. 2655–2670
  31. Delattre JY, Krol G, Thaler HT, et al. Distribution of brain metastases. Arch Neurol. 1988;45:741–744
  32. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast–enhanced MR imaging. AJNR Am J Neuroradiol. 1991;12:293–300
  33. Markesbery WR, Brooks WH, Gupta GD, et al. Treatment for patients with cerebral metastases. Arch Neurol. 1978;35:754–756
  34. Cairncross JG, Kim JH, Posner JB, et al. Radiation therapy for brain metastases. Ann Neurol. 1980;7:529–541
  35. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final result of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1–9
  36. Berk L. An overview of radiotherapy trials for the treatment of brain metastases. Oncology. 1995;9:1205–1212
  37. Patchell RA, Tibbs PA, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500
  38. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol. 1993;33:583–590
  39. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29:711–717
  40. Fokstuen T, Wiking N, Rutqvist LE, et al. Radiation therapy in the managment of brain metastases from breast cancer. Breast Cancer Res Treat. 2000;62:211
  41. Gelber RD, Larson M, Borgelt BB, et al. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981;48:1749–1753
  42. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49:650–655
  43. Slamon DI, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER 2/neu oncogene. Science. 1987;235:177–182
  44. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER2/NEU/neu in patients with axillary lymph node negative breast cancer. Cancer. 1995;75:1320–1326
  45. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/NEU/neu proto-oncogene in human breast and ovarian carcinoma. Science. 1989;244:707–712
  46. Ross JS, Fletcher JA. The HER2/NEU/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413–428
  47. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER 2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11:1936–1942
  48. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol. 1998;16:1340–1349
  49. Press MF, Bernastein L, Thomas PA, et al. HER2/NEU/neu gene amplification characterized by florescence in situ hybridization: poor prognosis in node negative breast carcinomas. J Clin Oncol. 1997;15:2894–2904
  50. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049–1056
  51. Lai RK, Dang C, Thaler H, et al. The incidence of brain metastases in HER 2/neu+stage IV breast cancer patients [abstract]. Proc Am Soc Clin Oncol. 2001;20:66b
  52. Weitzen R, Zach L, Kaufman B, et al. High incidence of brain metastases in patients on trastuzumab for advanced breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21:31b
  53. Wardley AM, Danson S, Clayton AJ, et al. High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center [abstract]. Proc Am Soc Clin Oncol. 2002;21:61a
  54. Heinrich B, Brudler O, Siekiera W, et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab [abstract]. Proc Am Soc Clin Oncol. 2003;22:37
  55. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–2977
  56. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;16:639–643
  57. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer. 2004;40:379–382
  58. Lower EE, Drosick RD, Blau R, et al. Increased rate of brain metastases with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer. 2003;4:114–119
  59. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;15:810–816
  60. Burstein HJ, Lieberman G, Slamon DJ, et al. Isolated central nervous system metastases in patients with HER2/NEU overexpressing advanced breast cancer treated with first-line trastuzumab based therapy [abstract]. Breast Cancer Res Treat. 2003;82:50–51
  61. Arif SS, Jordan CE, Thomas M, et al. A study to determine the incidence and treatment outcome of brain metastasis in patients treated with trstuzumab for metastatic breast cancer. Clin Oncol. 2004;16(Suppl):S44
  62. Atkinson J, Peace J, Crawford SM. Cerebral metastases in patients with advanced breast cancer treated with trasuzumab. Am J Clin Oncol. 2004;27:212
  63. Fuchs IB, Loebbecke M, Buhler H, et al. HER2/NEU in brain metastases: issues of concordance, survival and treatment. J Clin Oncol. 2002;20:4130–4133
  64. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18:2350–2351
  65. Edgerton SM, Merkel DE, More DH, et al. HER2/NEU/neu/ErbB-2 status by immunohistochemistry and FISH: clonality and progression with recurrence and metastases [abstract]. Breast Cancer Res Treat. 2001;64:55
  66. Ishida H, Sadahiro S, Suzuki T, et al. c-erbB-2 protein expression and clinicopathologic features in colorectal cancer. Oncol Rep. 2000;7:1229–1233
  67. Jimenez RE, Hussain M, Blanco FJ, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7:2440–2447
  68. Akatsuka T, Wada T, Kokai Y, et al. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology. 2001;60:361–366
  69. Boettcher B, Kahlert S, Bauerfeind I, et al. Losts of HER 2 overexpression during herceptin therapy in metastatic breast cancer [abstract]. Breast Cancer Res Treat. 2000;64:109
  70. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714–2721
  71. Nichols DW, Wolff DJ, Self S, et al. A testing algorithm for determination of HER2/NEU status in patients with breast cancer. Ann Clin Lab Sci. 2002;32:3–11
  72. Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison on fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651–3664
  73. Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19:354–363
  74. Cobleigh M, Vogel C, Tripathy D, et al. Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy [abstract]. Eur J Cancer. 2001;37(suppl 6):S192
  75. Harris LN, Liotcheva V, Broadwater G, et al. Comparison of methods of measuring HER2/NEU in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001;19:1698–1706
  76. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER2/NEU/neu status in breast cancer: Automated Cellular Imaging System (ACIS) assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495–503
  77. Cianciulli AM, Botti C, Coletta AM, et al. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER2/NEU in breast cancer. Cancer Genet Cytogenet. 2002;133:66–71
  78. Lear-Kaul KC, Yoon H, Kleinschmidt-DeMasters BK, et al. HER2/NEU/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med. 2003;127:1451–1457
  79. Grossi PM, Ochiai H, et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res. 2003;9:5514–5520
  80. Qin DX, Zheng R, Tang J, et al. Influence of radiation on the blood brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990;19:1507–1510
  81. van Vulpen M, Kal HB, Taphoorn MJB, et al. Changes in blood–brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002;9:683–688
  82. Rappaport SI. Osmotic opening of the blood–brain barrier: principles, mechanism, and therapeutic applications. Cell Moll Neurobiol. 2000;20:217–230
  83. Thomas HD, Lind MJ, Ford J, et al. Pharmacokinetics of carboplatin administered in combination with bradykinin agonist Cereport (RMP) for the treatment of brain tumors. Cancer Chemother Pharmacol. 2000;45:284–290
  84. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637–647

PII: S0305-7372(05)00082-4

doi: 10.1016/j.ctrv.2005.04.008

Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 312-318 , June 2005

Article Tools